MedTrace Logo

Comparison of Single-Dose Tranexamic Acid Vs. Placebo in Ovarian Cancer Surgery

NCT06879353 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 372

Last updated 2025-03-19

No results posted yet for this study

Summary

This study evaluated the effectiveness of a single dose of tranexamic acid compared to a placebo in reducing blood loss and the need for blood transfusions in women undergoing surgery for ovarian cancer. Tranexamic acid, a medication that helps control bleeding by stabilizing blood clots, has been widely used in other surgical settings but has not been well studied in ovarian cancer surgery.

Participants were randomly assigned to receive either a single dose of tranexamic acid or a placebo before surgery. Blood loss was measured during and after the procedure, and the need for blood transfusions was recorded. The study aimed to determine whether tranexamic acid was effective in reducing perioperative blood loss and minimizing the need for transfusions.

The findings contributed to understanding whether this cost-effective and widely available medication could improve surgical outcomes and reduce complications associated with excessive bleeding in ovarian cancer patients.

Conditions

Interventions

DRUG

Tranexamic Acid (TXA)

A single intravenous dose of tranexamic acid (15 mg/kg) was administered before surgery to assess its efficacy in reducing perioperative blood loss and the need for transfusion.

DRUG

Placebo

An equal volume of intravenous normal saline was administered as a placebo before surgery to compare outcomes with the tranexamic acid group.

Sponsors & Collaborators

  • Sheikh Zayed Medical College

    lead OTHER_GOV

Principal Investigators

  • Kainat Usman · Sheikh Zayed Medical college/Hospital, Rahimyar Khan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-12
Primary Completion
2024-07-12
Completion
2024-07-12

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06879353 on ClinicalTrials.gov